FLAVOCOXID: A MEDICAL FOOD THERAPY FOR OSTEOARTHRITIS

FLAVOCOXID:骨关节炎的医疗食品疗法

基本信息

  • 批准号:
    7603212
  • 负责人:
  • 金额:
    $ 3.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-01 至 2008-02-29
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OA is a leading chronic disease in older adults and is characterized by degeneration of articular cartilage of the joints in hands, spine, knees, and hips. In joints, tissue injury and pain are caused by the conversion of arachidonic acid to such inflammatory compounds as cyclooxygenases-1 and -2 (COX-1 and -2) and 5-lipoxygenase (5-LO). Conventional NSAIDs inhibit COX-1 and -2, but have little or no effect on 5-LO. NSAIDs provide relief from the pain of OA; however, NSAIDS are also associated with significant side effects, including gastrointestinal bleeding, venous thrombosis, and nephrotoxicity. Novel alternative therapies with increased safety and efficacy with fewer or no side effects are desirable; plant-derived substances might be useful alternatives to NSAIDs. Flavocoxid, a botanical extract derived from two plants, Scutellaria baicalensis and Acacia catechu, has been shown to inhibit COX-1 and -2 as well as 5-LO. The purpose of this study is to evaluate the safety and efficacy of flavocoxid in relieving the symptoms of knee OA in adults. This study will last 12 weeks. Participants will be randomly assigned to one of two groups. Group 1 participants will receive daily flavocoxid; Group 2 participants will receive placebo. There will be 5 study visits: study entry and Weeks 2, 4, 8, and 12. Joint pain, tenderness, and swelling will be assessed at each study visit. A 30-foot timed walking test will also be performed at all visits. A physical exam and blood collection will occur at study entry and Week 12. Other study assessments will include safety monitoring, patient/physician global disease ratings, quality of life measures, depression and anxiety ratings, and measures of efficacy as determined by the Western Ontario and McMaster (WOMAC) OA index.
该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 OA是老年人的主要慢性疾病,其特征在于手、脊柱、膝和髋关节的关节软骨退化。在关节中,组织损伤和疼痛是由花生四烯酸转化为诸如环氧合酶-1和-2(考克斯-1和-2)和5-脂氧合酶(5-LO)的炎性化合物引起的。常规NSAID抑制考克斯-1和-2,但对5-LO几乎没有影响。NSAID可缓解OA疼痛;然而,NSAID也与显著的副作用相关,包括胃肠道出血、静脉血栓形成和肾毒性。新的替代疗法,增加安全性和有效性,较少或没有副作用是可取的;植物源性物质可能是有用的替代非甾体抗炎药。Flavocoxid是一种来自两种植物黄芩和儿茶的植物提取物,已显示出抑制考克斯-1和-2以及5-LO。本研究的目的是评价黄酮环氧化酶在缓解成人膝关节OA症状方面的安全性和有效性。 本研究将持续12周。参与者将被随机分配到两组之一。第1组受试者将接受每日flavocoxid;第2组受试者将接受安慰剂。将进行5次研究访视:研究入组和第2、4、8和12周。将在每次研究访视时评估关节疼痛、压痛和肿胀。还将在所有访视时进行30英尺定时步行试验。将在入组研究和第12周时进行体格检查和采血。其他研究评估将包括安全性监测、患者/医生总体疾病评级、生活质量测量、抑郁和焦虑评级以及由西安大略和麦克马斯特(WOMAC)OA指数确定的疗效测量。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SARAH LUISE MORGAN其他文献

SARAH LUISE MORGAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SARAH LUISE MORGAN', 18)}}的其他基金

Flavocoxid: A Medical Food Therapy for Osteoarthritis
黄酮氧化:治疗骨关节炎的医疗食品疗法
  • 批准号:
    6787596
  • 财政年份:
    2004
  • 资助金额:
    $ 3.74万
  • 项目类别:
MECHANISMS OF ANTIFOLATE EFFICACY
抗叶酸功效的机制
  • 批准号:
    6565402
  • 财政年份:
    2001
  • 资助金额:
    $ 3.74万
  • 项目类别:
MECHANISMS OF ANTIFOLATE EFFICACY
抗叶酸功效的机制
  • 批准号:
    6410718
  • 财政年份:
    2000
  • 资助金额:
    $ 3.74万
  • 项目类别:
COMBINATION METHOTREXATE AND FOLIC ACID FOR ARTHRITIS
甲氨蝶呤和叶酸联合治疗关节炎
  • 批准号:
    6137337
  • 财政年份:
    2000
  • 资助金额:
    $ 3.74万
  • 项目类别:
MECHANISMS OF ANTIFOLATE EFFICACY
抗叶酸功效的机制
  • 批准号:
    6303017
  • 财政年份:
    1999
  • 资助金额:
    $ 3.74万
  • 项目类别:
MECHANISMS OF ANTIFOLATE EFFICACY
抗叶酸功效的机制
  • 批准号:
    6274097
  • 财政年份:
    1998
  • 资助金额:
    $ 3.74万
  • 项目类别:
MECHANISMS OF ANTIFOLATE EFFICACY
抗叶酸功效的机制
  • 批准号:
    6112863
  • 财政年份:
    1998
  • 资助金额:
    $ 3.74万
  • 项目类别:
5 AMINOIMIDAZOLE 4 CARBOXAMIDE IN PSORIASIS PATIENTS URINE TAKING METHOTREXATE
5 氨基咪唑 4 甲酰胺在银屑病患者尿液中服用甲氨蝶呤
  • 批准号:
    6244013
  • 财政年份:
    1997
  • 资助金额:
    $ 3.74万
  • 项目类别:
MECHANISMS OF ANTIFOLATE EFFICACY IN ARTHRITIS
抗叶酸治疗关节炎的功效机制
  • 批准号:
    6055603
  • 财政年份:
    1996
  • 资助金额:
    $ 3.74万
  • 项目类别:
MECHANISMS OF ANTIFOLATE EFFICACY IN ARTHRITIS
抗叶酸治疗关节炎的功效机制
  • 批准号:
    2769605
  • 财政年份:
    1996
  • 资助金额:
    $ 3.74万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 3.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了